Close Menu

NEW YORK (GenomeWeb) – Editas Medicine has exclusively licensed a newly released CRISPR enzyme from Integrated DNA Technologies for human therapeutic applications, IDT said today.

The new enzyme, Alt-R Cas12a (Cpf1) Ultra is a mutant of Acidaminococcus sp. BV3L6 Cas12a (Cpf1) that has enhanced editing activity, reaching or exceeding the performance of Cas9, according to IDT. The new enzyme also retains activity across a wider temperature range than the wild-type enzyme, making it useful for genome editing in additional organisms, including plants.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The US National Institutes of Health's All of Us project awarded $4.6 million to the company Color to develop a genetic counseling resource for the program.

The Times of India reports on a pilot study that used genomic testing to determine whether patients had drug-resistant tuberculosis.

New guidelines say that more women may benefit from genetic testing for hereditary breast or ovarian cancer, according to the Los Angeles Times.

In Cell this week: small proteins identified among human microbiome, role for tumor microbes in pancreatic cancer survival, and more.

Aug
28
Sponsored by
Horizon Discovery

This webinar will provide an overview of alternatives to the popular Cas9 nuclease used in CRISPR gene editing.

Oct
23
Sponsored by
Swift Biosciences

This webinar will illustrate how single-cell methylation sequencing can be applied to gain significant insight into epigenetic heterogeneity in disease states, advancing cancer research discoveries.